We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




A Better Way to Deliver Dendritic Cell Vaccines

By Biotechdaily staff writers
Posted on 20 May 2002
An animal study has shown that a new method of delivering dendritic cell vaccines is much faster and less expensive than the conventional method. More...
Conducted by scientists at the University of Texas Southwestern Medical Center (UT, Dallas, USA), the study was published in the December 28, 2002, issue of Nature Biotechnology.

Dendritic cells signal T lymphocytes to multiply and initiate an immune response against bacteria, viruses, and cancer cells and are thus good vaccine candidates. However, the conventional method of culturing cells in a petri dish is a time-consuming, expensive process that has deterred broad vaccine application. Now, a new procedure developed and tested in mice enables researchers to manipulate dendritic cells in the skin instead of a petri dish and reduces the time required from 10 days to 24 hours.

Here is how the new delivery method works. Upon exposure to the chemical hapten, immature dendritic cells in the epidermis known as Langerhans cells mature and migrate to draining lymph nodes. A key chemokine (MIP3beta) helps to attract the migrating cells and mediate the migration process. The researchers created an artificial trap for Langerhans cells by implanting a polymer rod under the skin that was synthesized with ethylene-vinyl-acetate to release this chemokine. After the rod was implanted, hapten was applied to trigger the Langerhans cell migration. The cells homed in to the lymph nodes and created an accumulation of Langerhans cells around the rod.

In a second experiment, the researchers utilized a polymer rod releasing a tumor-associated antigen that was implanted under the skin, believing that the Langerhans cells would carry the antigen to the draining lymph nodes and initiate immunity against tumor development. Subsequent experiments with different tumor models have demonstrated that this strategy is efficacious.

"We believe that our in situ Langerhans cell vaccine format represents a breakthrough in the tumor vaccines field, thus moving it toward practical medicine,” said Dr. Akira Takashima, professor of dermatology at UT Southwestern.




Related Links:
University of Texas Southwestern Medical Center

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Automated Clinical Chemistry Analyzer
Envoy 500+
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.